{"id":24836,"date":"2025-09-22T16:25:58","date_gmt":"2025-09-22T21:25:58","guid":{"rendered":"https:\/\/autism.org\/?p=24836"},"modified":"2025-09-26T15:27:46","modified_gmt":"2025-09-26T20:27:46","slug":"acetaminophen-leucovorin","status":"publish","type":"post","link":"https:\/\/autism.org\/acetaminophen-leucovorin\/","title":{"rendered":"ARI Statement on Acetaminophen, Leucovorin and Autism"},"content":{"rendered":"
<\/div>

September 22, 2025
\n5 pm Eastern Time, US<\/p>\n

FOR IMMEDIATE RELEASE<\/p>\n

ARI Statement on Prenatal Acetaminophen Use, Leucovorin, and Autism<\/h3>\n

The Autism Research Institute (ARI) provides the following statement in response to recent media inquiries regarding potential connections between prenatal acetaminophen use, leucovorin supplementation, and autism spectrum disorders (ASD).<\/p>\n

ARI’s Commitment to Evidence-Based Research<\/strong><\/p>\n

ARI is committed to monitoring ongoing research and sharing accurate, evidence-based information with autistic people, families, researchers, and policymakers. This includes addressing questions about environmental influences and potential medical factors, such as the use of over-the-counter medications.<\/p>\n

\u201cWe know there are subtypes of autism, with no single cause explaining the condition and no single intervention benefiting everyone on the spectrum. Research should focus on understanding these differences rather than generalizing findings to every autistic individual,\u201d said ARI Chief Science Officer, Dr. Steve Edelson. \u201cBy identifying unique biological, developmental, and environmental factors within each subtype, we can begin to develop more targeted, effective approaches.\u201d<\/p>\n

Acetaminophen Research<\/strong><\/p>\n

The Autism Research Institute acknowledges that recent studies have examined potential associations between prenatal acetaminophen (commonly known as Tylenol in the U.S.) exposure and autism. While these studies contribute to our understanding of possible risk factors, ARI maintains that the current evidence does not establish a definitive causal relationship between acetaminophen use during pregnancy and autism.<\/p>\n

Extensive studies, including a 2024 Swedish study analyzing nearly 2.5 million births, suggest that observed associations between prenatal acetaminophen use and autism may reflect familial confounding rather than a direct causal link. Research led by Dr. Mady Hornig of Columbia University underscores the complexity of these factors. Her work highlights the role of maternal immune responses and fever, showing that inflammation during pregnancy may affect neurodevelopment independently of medication use. Preliminary evidence also indicates that acetaminophen taken to reduce fever may be neutral\u2014or even potentially protective\u2014though these findings remain inconclusive.<\/p>\n

Leucovorin (Folinic Acid) Research<\/strong><\/p>\n

ARI has supported Dr. Richard Frye\u2019s research related to leucovorin<\/a> (folinic acid) as a potential intervention in autism, particularly for individuals with metabolic differences such as impaired methylation or glutathione production. We are encouraged by the preliminary results suggesting that leucovorin supplementation may benefit certain subgroups<\/a> of individuals with autism spectrum disorders.<\/p>\n

Dr. Frye’s work represents potential progress in understanding possible biomarker-based approaches to intervention. However, we emphasize that this research is still evolving, and larger, controlled studies are needed to fully validate these findings and establish optimal treatment protocols.<\/p>\n

It is important to note that Dr. Frye’s leucovorin research explores potential therapeutic interventions rather than causative factors and should not be interpreted as supporting any specific theory about acetaminophen causation.<\/p>\n

Ongoing Commitment<\/strong><\/p>\n

ARI remains committed to supporting rigorous, scientifically sound research into all aspects of autism spectrum disorders. We encourage:<\/p>\n